Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies-Reference-Cited by-同舟云学术

Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies

Published:2023-01-26 Issue:4 Volume:28 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Arashiro Takeshi¹²³⁴,Arima Yuzo⁴,Kuramochi Jin⁵⁶,Muraoka Hirokazu⁷,Sato Akihiro⁸,Chubachi Kumi⁹,Oba Kunihiro¹⁰,Yanai Atsushi¹¹,Arioka Hiroko¹¹,Uehara Yuki¹²¹³,Ihara Genei¹⁴,Kato Yasuyuki¹⁵,Yanagisawa Naoki¹⁶,Nagura Yoshito¹⁷,Yanai Hideki¹⁸,Ueda Akihiro¹⁹,Numata Akira²⁰,Kato Hideaki²¹,Oka Hideaki²²,Nishida Yusuke²²,Ooki Takao²³,Nidaira Yuki⁶,Stucky Ashley⁴,Suzuki Tadaki³,Smith Chris¹²,Hibberd Martin²,Ariyoshi Koya¹,Suzuki Motoi⁴

Affiliation:

1. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

2. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

3. Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan

4. Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan

5. Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan

6. Kuramochi Clinic Interpark, Tochigi, Japan

7. CLINIC FOR Tamachi, Tokyo, Japan

8. KARADA Internal Medicine Clinic, Tokyo, Japan

9. Chubachi Internal Respiratory Medicine Clinic, Tokyo, Japan

10. Department of Pediatrics, Showa General Hospital, Tokyo, Japan

11. Department of General Internal Medicine, St. Luke’s International Hospital, Tokyo, Japan

12. Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan

13. Department of Clinical Laboratory, St. Luke’s International Hospital, Tokyo, Japan

14. Machida Ekimae Naika Clinic, Tokyo, Japan

15. Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan

16. Yanagisawa Clinic, Tokyo, Japan

17. Shinjuku Home Clinic, Tokyo, Japan

18. Fukujuji Hospital, Japan Anti-Tuberculosis Association, Kiyose, Japan

19. Department of Infectious Diseases, Japanese Red Cross Medical Center, Tokyo, Japan

20. Ikebukuro Metropolitan Clinic, Tokyo, Japan

21. Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan

22. Department of General Internal Medicine and Infectious Diseases, Saitama Medical Center, Saitama, Japan

23. Saitama Sekishinkai Hospital, Saitama, Japan

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference8 articles.

1. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.;van Ewijk;Euro Surveill,2022

2. World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination: interim guidance, 1 October 2022: second addendum to Evaluation of COVID-19 vaccine effectiveness: interim guidance. Geneva: WHO; 2022. Available from: https://apps.who.int/iris/handle/10665/363344

3. Government of the Netherlands. Netherlands to reopen further with coronavirus entry passes. Amsterdam: Government of the Netherlands; 2021. Available from: https://www.government.nl/latest/news/2021/09/14/netherlands-to-reopen-further-with-coronavirus-entry-passes

4. Community and close contact exposures associated with COVID-19 among symptomatic adults ≥18 years in 11 outpatient health care facilities – United States, July 2020.;Fisher;MMWR Morb Mortal Wkly Rep,2020

5. Behavioral factors associated with SARS-CoV-2 infection in Japan.;Arashiro;Influenza Other Respir Viruses,2022